Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.
For an indepth analysis of these deals, read 'Pharma deals during January 2015'
Licensor acquired / licensee acquirer | Product / technology | Deal type | Headline ($m) |
NPS/Shire | NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome | Corporate acquisition | 5,200 |
Foundation Medicine/Roche | Broad R&D collaboration to optimise oncology treatments via Foundations genomic analysis and molecular information | Majority interest acquisition | 1,180 |
Kite Pharma/Amgen | Chimeric Antigen Receptor (CAR) T cell immunotherapy engineered autologous cell therapy (eACT) platform, Amgen contribute cancer targets | Licence collaboration agreement | 1,110 |
Janssen/ Depomed | Nucynta [tapentadol] franchise including extended release tablets and oral solutions | Divestment of US rights | 1,050 |
Esteve/ Mundipharma | Discovery and development of next generation pain products including E-52862 in P2 for neuropathic pain | Strategic collaboration | 1,000 |
Isis/ Janssen | Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes) | Collaboration to discover and develop candidates | 835 |
Fedora and Meiji Seika/Roche | Roche secures rights to OP0595 a beta lactamase inhibitor in P1 clinical development against multi drug resistant bacteria | Licence agreement | 750 |
Convergence/Biogen Idec | Includes a neuropathic pain portfolio with CNV 1014802 in P2 for trigeminal neuralgia | Corporate acquisition | 675 |
Trophos/Roche | Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury | Corporate acquisition | 545 |
Cytos Biotechnology/ OnCore | Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases | Exclusive licence | 522 |
AC Immune/ Janssen | To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease | 3 year research collaboration and exclusive licence | 509 |
Neuropore Therapies/UCB | To develop and commercialise NPT200-11 and other therapeutic products for Parkinson's disease | Collaboration agreement | 480 |
PneumRx/BTG | Includes RePneu a coil to open airways in emphysema patients | Corporate acquisition | 475 |
Phenex/Gilead | Small molecules targeting FXR Farnesoid X receptor (FXR) programme Px102, Px104 in P2 development in Non-Alcoholic Steatohepatitis [NASH] | Asset acquisition | 470 |
Auden Mckenzie/Actavis | Purchase includes generic portfolio of 175 products making Actavis no 1 generic supplier in the UK | Corporate acquisition | 458 |
Agenus/Incyte | Using Agenus' antibody discovery platform focusing on 4 checkpoint modulator programmes includes $35m equity | Licence to develop and commercialise | 410 |
Aurigene /Curis | 2 programmes including IRAK4 Inhibitors and small molecule antagonist of programmed death [PD-L1] | Collaboration and option to a licence | 346 |
Vedanta /J&J | Microbiome-based drug candidate VE202 for bowel diseases, Crohn's disease and ulcerative colitis | Licence to develop anti-bacterial VE202 | 241 |
OnCyte/Cardio3 | Acquisition of the oncology division of Celdara Medical including CM-CS1 an autologous CAR-T cell drug candidate which uses NKG2D to target tumour antigens | Asset acquisition | 180 |
ZymeWorks/Celgene | Development of multiple bi-specific antibodies using the Azymetric platform | Licence, option and collaboration | 164 |
Novartis/Aspen | Purchase of the heparin based anticoagulant Mono-Embolex, with sales of €68m in 2013 | Asset acquisition | 142 |
Amunix/Naia | To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel syndrome | 2 exclusive licences | 140 |